

Market Snapshot

November 20, 2020

Market Snapshot (Updated at 8AM)

Indian Indices	Close	Net Chng.	Chng. (%)		
Sensex	43599.96	580.09	1.31		
Nifty	12771.70	166.55	1.29		

Global Indices	Close	Net Chng.	Chng. (%)
DOW JONES	29483.23	44.81	0.15
NASDAQ COM.	11904.71	103.11	0.87
FTSE 100	6334.35	50.89	0.80
CAC 40	5474.66	36.79	0.67
DAX	13086.16	115.73	0.88
NIKKEI 225	25483.01	143.53	0.56
SHANGHAI	3365.29	2.35	0.07
HANG SENG	26425.97	66.80	0.25

Currency	Close	Net Chng.	Chng. (%)
USD / INR	74.27	0.08	0.10
USD / EUR	1.19	0.00	0.22
USD / GBP	1.33	0.00	0.14
USD / JPY	103.87	0.05	0.05

Precious Metals	Close	Net Chng.	Chng. (%)
Gold (USD)	1863.17	3.29	0.18
Silver	24.23	0.07	0.27

Energy	Close	Net Chng.	Chng. (%)
NYMEX Crude	41.74	0.00	0.00
Brent Crude	44.20	0.02	0.05
Natural Gas	2.61	0.02	0.85

Bond	Close	Net Chng.	Chng. (%)
10 Yrs G-Sec	5.88	0.00	0.02

Indian ADRs	Close	Net Chng.	Chng. (%)
Dr. Reddy's Lab	63.04	0.43	0.69
HDFC Bank	66.62	0.54	0.80
ICICI Bank	13.03	0.24	1.81
Infosys Ltd	14.83	0.16	1.07
Tata Motors	11.58	0.05	0.43
Vedanta Ltd	6.14	0.18	3.02
Wipro	4.99	0.07	1.38

Institutional Flow (In Crore) 19-11-2020

Institution	Purchase	Sale	Net
FII	10852.05	9671.44	1180.61
DII	3162.07	6017.01	2854.94

Key Contents

- ⇒ Market Outlook/Recommendation
- ⇒ Today's Highlights
- ⇒ Global News, Views and Updates
- ⇒ Links to important News highlight

Top News for Today

- Reliance Industries: Reliance Retail Ventures has received a total of Rs 47,265 crore from 9 financial partners and allotted 10.09% stake and has completed the current phase of raising funds.
- Bharti Infratel: Merger of Indus Towers into the company has been completed.
 Vodafone Idea has received cash worth Rs 3,760 crore for its 11.5% shareholding in Indus.
- Infosys: The company's arm 'Simplus' has announced a vaccine management solution aligned with salesforce work.com for vaccines.
- Apollo Hospitals: Announces collaboration with Tata Medical and Diagnostics to introduce Covid-19 testing across India. To begin with 10,000 tests in NCR from the first week of December and then follow with a national rollout.
- Mphasis: Acquired data engineering and consultancy company Datalytyx for 13.3 million pounds.
- Adani Enterprises: Raised Rs 34.3 crore by allotment of 343 secured, rated, listed, redeemable, principal protected market linked NCDs worth Rs 10 lakh each on a private placement basis. The NCDs will be listed on the wholesale debt market segment of BSE.
- South Indian Bank: Revised MCLR rates from November 20. One-month MCLR at 7.95% and one-year MCLR at 8.2%.
- Tata Steel: HDFC Mutual Fund decreased its stake to 2.96% from 5.02% on November 12.
- Aarti Industries: HDFC Mutual Fund reduced its stake to 5.08% from 7.08% on November 17.
- Syngene International: Signs five-year strategic collaboration with Deerfield
 Discovery and Development Corporation, where 3DC has chosen Syngene as a
 key execution partner for a developing portfolio of molecular entities, spanning
 multiple therapeutic areas and modalities.
- Emami: Entered into home hygiene products segment with the launch of Emasol brand. Products include disinfectant floor cleaner, toilet cleaner, sanitizer, dish wash gel and bathroom cleaner.
- Zee Learn: L&T Infra Finance increased stake by 1.26 crore shares via off market transfer from security trustee & appropriated against loan outstanding amounts on November 18. L&T Finance and L&T Infra Finance now hold 6.8% stake in the company.

Events of the Day

- Conference call: 10:00 AM Bajaj Electric, 11:30 AM Compuage Info, 11:30 AM Visaka Ind, 3:30 PM Power Mech, 4:00 PM Arman Financial, 4:00 PM Cochin Shipyard, 4:00 PM NGL Fine Chem, 4:00 PM IFGL Refractor, 5:30 PM Sintercom India
- **Dixon Tech:** To meet Franklin Templeton on November 26.
- CAMS: To meet Yes Securities, Franklin Templeton AMC and other investors between November 23 - December 4.
- Eicher Motors: To meet Amundi Pioneer, AIA International and other investors between November 20-24.





Market in Detailed	Updai	ted at 8AM)
Trialites in Detailed	9 9 9 9	

Indian Indices	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Sensex	43599.96	580.09	1.31	0.56	7.54	14.08	7.25
Nifty	12771.70	166.55	1.29	0.64	7.35	12.90	6.44
BSE M Cap	16237.63	106.22	0.65	3.16	9.90	9.20	9.21
BSE S Cap	16059.06	5.48	0.03	3.83	7.81	11.35	19.71
Nifty MC 100	18802.30	121.85	0.64	3.41	10.45	11.26	10.64
BSE Auto	19491.56	137.68	0.70	4.22	9.16	9.20	7.80
BSE Capgoods	16858.32	10.07	0.06	6.27	22.36	19.90	5.56
BSE FMCG	11464.54	52.33	0.46	0.62	3.29	1.75	2.47
BSE Metal	9594.29	115.43	1.19	3.80	14.95	3.92	2.11
BSE Oil&Gas	12906.92	58.24	0.45	0.23	7.87	3.69	16.47
BSE Healthcare	19628.78	59.01	0.30	0.29	0.73	2.83	45.70
BSE Power	1927.26	14.61	0.76	3.83	19.45	13.69	0.02
BSE Realty	1970.72	28.65	1.43	4.60	10.24	12.94	6.17
BSE ConsDur	25972.68	196.29	0.76	1.95	6.32	13.16	3.15
BSE Bank	33205.95	939.36	2.75	2.38	20.34	33.03	6.36
BSE IT	21263.06	147.81	0.69	1.47	3.53	16.12	39.95

LME	Index	Net Chng	%1D	%5D	%1M	%3М	%1Y
Gold(\$/Ounce)	1863.17	3.29	0.18	1.37	2.29	4.31	26.61
Silver(\$/Ounce)	24.05	0.00	0.01	2.51	2.40	11.73	40.23
Aluminium	1980.35	4.40	0.22	3.56	7.79	12.63	14.22
Copper	7076.25	6.75	0.10	2.32	4.70	5.64	20.81
Zinc	2753.55	11.55	0.42	5.49	11.31	10.83	16.45
Lead	1962.75	31.25	1.62	4.30	12.95	1.38	1.13

Currency	Rate	Net Chng	%1D	%5D	%1M	%3М	%1Y
INR	74.27	0.08	0.10	0.51	1.22	0.74	3.44
USD Index	92.34	0.04	0.05	0.45	0.79	0.49	5.72
YUAN	6.58	0.00	0.05	0.39	1.45	5.09	6.90
GBP	1.33	0.00	0.05	0.49	2.36	0.30	2.55
EUR	1.19	0.00	0.03	0.32	0.42	0.10	7.22
YEN	103.87	0.13	0.13	0.73	1.57	1.86	4.56

Agro Commodities	Price	Net Chng	%1D	%5D	%1M	%3М	%1Y
Coffee	123.20	0.35	0.28	9.07	13.08	1.61	4.94
Cotton	71.73	0.06	0.08	1.89	0.04	9.65	6.13
Sugar	15.28	0.17	1.10	2.41	3.80	11.05	11.53
Wheat	599.75	1.00	0.17	0.37	5.10	12.10	9.14
Soybean	1186.00	8.50	0.72	3.31	11.49	30.08	24.45

Global Indices	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Dow Jones	29483.23	44.81	0.15	1.39	4.15	6.29	5.97
Nasdaq	11904.71	103.11	0.87	1.67	3.37	5.68	39.62
S&P 500	3581.87	14.08	0.39	1.27	4.03	5.80	15.23
FTSE100	6334.35	50.89	0.80	0.07	7.56	5.34	12.78
CAC40	5474.66	36.79	0.67	2.09	11.06	11.47	7.12
DAX	13086.16	115.73	0.88	0.25	2.74	2.00	0.55
Mexico IPC	41868.82	383.79	0.91	2.47	9.60	8.17	3.98
Brazil Bovespa	106669.9	550.80	0.52	4.06	6.10	5.13	0.76
Russian RTS	1258.91	17.84	1.40	1.65	10.36	1.09	13.08
Japan Nikkei	25483.01	143.53	0.56	0.41	8.16	11.41	10.12
Hang Seng	26425.97	66.80	0.25	1.02	7.55	6.58	1.73
Taiwan Index	13683.78	38.89	0.28	3.09	6.38	10.68	17.65
Shanghai Comp	3365.29	2.35	0.07	1.67	1.12	0.05	15.61
KOSPI	2547.30	0.82	0.03	2.18	8.05	12.05	19.90
Malaysia KLCI	1586.12	2.51	0.16	0.22	4.98	0.69	0.93
Jakarta Comp	5596.31	6.30	0.11	2.55	9.81	6.21	9.01
Philippine SE	7070.89	71.73	1.03	1.43	15.65	17.72	10.49
Thai Exch	1369.42	4.83	0.35	2.48	13.11	5.60	14.24
Freight	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y

Energy Markets	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
NYMEX Crude	41.74	0.00	0.00	4.01	0.68	1.97	26.91
BRENT Crude	44.20	0.02	0.05	3.27	1.49	4.72	23.95
Natural Gas	2.61	0.02	0.85	12.72	19.82	16.65	1.21

0.27

1.39

74.42

0.80

5.81

17.41

3.31

26.55

10.45

200.00 676.92

11.51

64.62

Bond Markets	Yield	Net Chng	%1D	%5D	%1M	%3M	%1Y
US	0.82	0.00	0.59	8.02	4.93	26.66	52.75
UK	0.32	0.01	4.15	7.18	91.12	36.86	55.94
Brazil	3.34	0.01	0.33	0.45	6.94	10.72	14.43
Japan	0.01	0.01	38.89	56.00	50.00	69.44	110.38
Australia	0.85	0.03	3.72	3.07	12.67	0.00	20.41
India	5.88	0.00	0.02	0.05	1.06	1.54	9.28
Switzerland	0.49	0.01	2.92	5.11	9.19	4.00	7.14
Germany	0.57	0.02	3.07	6.53	9.08	20.98	68.44

Baltic Dry

Baltic Dirty

SG Dubai HY

1115.00

437.00

3.00

6.00

0.32



Taking global cues, Nifty is expected to open flat around 12,800 and likely to remain range-bound in the price band of 12,850-12,600.

The Nifty previous session ended 1.29% down at 12,771.70. It opened gap-down and retraced back from days towards finishing off below early morning low with a bearish shooting star candle. Needless to say, we prefer being cautious on rise around 12,850 levels. Breaking down 12,750 may stimulate further downside towards 12,600 levels.

On the Nifty hourly chart; RSI and Stochastic both declined sharply following aggressive sell off in the last hour. –DI +DI bearish crossover brightens the possibility of further decline towards 12,600 levels.

Nifty patterns on multiple time frames suggest; finishing off with a bearish shooting star is a concern. Staying cautious on rise is advised.

The Bank Nifty previous session ended 2.85% up at 28,903.05. It might get into the trading range of 28,300-29,300.

Nifty Crucial Supports & Resistances-Supports- 12750, 12600 Resistances- 12850, 12900

Open Positional Calls-

T+7 Positional Buy-|Cash Segment| CESC @ 580-575, TGT- 605 & 625, SL- 550

T+3 Positional Buy-

|Cash Segment| BHARAT FORGE @ 495-494, TGT- 524, SL- 479

T+5 Positional Buy-

|Cash Segment| VOLTAS @ 770-765, TGT-805, SL-745

T+5 Positional Buy-

|Cash Segment| ASHOK LEYLAND @ 93-92, TGT- 100, SL- 88

T+3 Positional Sell-

|Futures Segment | TATA CHEM Fut @ 351-353, TGT-333, SL-above 363



Today's Highlights



- **Reliance Industries:** Reliance Retail Ventures has received a total of Rs 47,265 crore from 9 financial partners and allotted 10.09% stake and has completed the current phase of raising funds.
- **Bharti Infratel:** Merger of Indus Towers into the company has been completed. Vodafone Idea has received cash worth Rs 3,760 crore for its 11.5% shareholding in Indus. Board allotted 75.8 crore shares of Rs 10 each to the Vodafone Group and 8.75 crore shares to P5 Asia Holding Investments aggregating to 28.12% and 3.25% respectively in the post-issue share capital of the company.
- **Infosys:** The company's arm 'Simplus' has announced a vaccine management solution aligned with salesforce work.com for vaccines.
- Apollo Hospitals: Announces collaboration with Tata Medical and Diagnostics to introduce Covid-19 testing
 across India. To begin with 10,000 tests in NCR from the first week of December and then follow with a
 national rollout.
- Mphasis: Acquired data engineering and consultancy company Datalytyx for 13.3 million pounds.
- Adani Enterprises: Raised Rs 34.3 crore by allotment of 343 secured, rated, listed, redeemable, principal
 protected market linked NCDs worth Rs 10 lakh each on a private placement basis. The NCDs will be listed
 on the wholesale debt market segment of BSE.
- **South Indian Bank:** Revised MCLR rates from November 20. One-month MCLR at 7.95% and one-year MCLR at 8.2%.
- Tata Steel: HDFC Mutual Fund decreased its stake to 2.96% from 5.02% on November 12.
- Aarti Industries: HDFC Mutual Fund reduced its stake to 5.08% from 7.08% on November 17.
- **Syngene International:** Signs five-year strategic collaboration with Deerfield Discovery and Development Corporation, where 3DC has chosen Syngene as a key execution partner for a developing portfolio of molecular entities, spanning multiple therapeutic areas and modalities.
- **Emami:** Entered into home hygiene products segment with the launch of Emasol brand. Products include disinfectant floor cleaner, toilet cleaner, sanitizer, dish wash gel and bathroom cleaner.
- Route Mobile: Chandrakant Gupta stepped down as Chairman and will be replaced by Sandipkumar Gupta.
- **Zee Learn:** L&T Infra Finance increased stake by 1.26 crore shares via off market transfer from security trustee & appropriated against loan outstanding amounts on November 18. L&T Finance and L&T Infra Finance now hold 6.8% stake in the company.

Global News & Views

U.S. Futures Slide After Spat Over Fed Stimulus

U.S. futures slid Friday after a dispute between Treasury Secretary Steven Mnuchin and the Federal Reserve on its emergency lending facilities. Asian stocks were mixed. S&P 500 contracts retreated after the Trump administration and the Fed publicly disagreed over whether to extend the pandemic programs. Stocks edged up in Australia, dipped in Japan and fluctuated in China. Treasury yields declined and the dollar ticked up. Gold held losses amid a drawdown in bullion-backed exchange-traded funds. Technology shares led U.S. benchmarks higher Thursday as investors weighed tougher virus curbs against the prospect of a vaccine rollout in the months ahead. Shares of firms seen as beneficiaries of lockdowns outperformed.

America's Biggest Oil Storage Hub is Filling to the Brim Again

Oil tanks in America's most important crude storage hub are filling to the brim once again, quickly approaching the critical levels reached in May after prices crashed. Stockpiles at Cushing, Oklahoma, the delivery point for West Texas Intermediate futures, stood at 61.6 million barrels as of Nov. 13, or about 81% of capacity, according to the most recent U.S. government data. That's 3.83 million barrels shy of the levels seen in May. Though a repeat of the negative oil prices seen in April is unlikely, the mounting supply glut brings home how lockdown measures to contain the Covid-19 pandemic may soon force traders to store oil in every nook and cranny available, including ships and pipelines. Some are already doing that. The reasons behind the build-up are similar to what happened before: Refineries are still coping with lacklustre demand as coronavirus cases surge anew. On top of that, some of them have also been undergoing seasonal maintenance.

Oil Pares Weekly Gain as Virus Surge Damps Vaccine Optimism

Oil trimmed a third weekly gain in New York as more restrictions were implemented in the U.S. to curb the spread of the coronavirus, raising concerns about the immediate demand outlook. Futures edged lower after slipping 0.2% on Thursday. The Centres for Disease Control and Prevention urged Americans not to travel for Thanksgiving, California ordered a one-month curfew and health experts found no evidence that a widely-used drug improves survival in patients. Adding to bearish sentiment was a clash between the Trump administration and the Federal Reserve over whether to extend the bank's emergency pandemic programs. Oil is still up almost 4% this week, however, after positive Covid-19 vaccine developments and signs of a robust recovery in Asian consumption boosted optimism for the demand outlook longer-term.

WHO Advises Doctors Not to Use Gilead's Remdesivir for Covid

The World Health Organization recommended against using Gilead Sciences Inc.'s remdesivir to treat hospitalized Covid-19 patients less than a month after U.S. regulators granted the drug a speedy approval. "There is currently no evidence that it improves survival or the need for ventilation," a panel of WHO-convened experts developing Covid-19 treatment guidelines said in The BMJ medical journal. The recommendation is a blow to Gilead's drug, which was one of the first thought to offer a meaningful benefit in treatment of coronavirus patients after a study showed it reduced their recovery time. The antiviral has been used widely to treat Covid and was among the drugs President Donald Trump received when he was diagnosed with the disease in early October.



Global News & Views

Tata's Jaguar Seeks to Block U.S. Imports of Porsches, Audis

You wouldn't know it was about Jags and Lambos, to judge by its rather dry name: In the Matter of Certain Vehicle Control Systems. But that's the complaint Jaguar Land Rover Automotive Plc filed on Thursday to block U.S. imports of Porsche, Lamborghini, Audi and Volkswagen sport utility vehicles it says are using its patented Terrain Response technology without permission. Jaguar Land Rover, a British carmaker owned by India's Tata Motors Ltd., said in its filing with the U.S. International Trade Commission that the technology helps negotiate a "broad range of surfaces" and is a key feature in Jaguar's F-Pace and Land Rover Discovery vehicles.

California Curfew; S. Australia Lifting Lockdown

South Korean Prime Minister Chung Sye-kyun urged citizens to stay home and cancel gatherings. South Australia will lift its lockdown early and immediately allow outdoor exercise, amid early signs its cluster of Covid-19 infections is being contained. The WHO advised against against using Gilead Sciences Inc.'s remdesivir for hospitalized coronavirus patients, despite U.S. regulators granting the drug a quick approval. California imposed a late-night curfew to battle a case surge. White House coronavirus task force coordinator Deborah Birx urged Americansto be vigilant as Covid-19 surges, but Vice President Mike Pence said Donald Trump opposed lockdowns and closing schools.

Mnuchin Wants \$580 Billion Injected into Slowing U.S. Economy

Treasury Secretary Steven Mnuchin said that lawmakers should redirect unspent stimulus funding, including money he's pulling back from the Federal Reserve, to buoy the economy as the U.S. waits for a coronavirus vaccine. "I hope that Congress will seriously consider reallocating \$580 billion of funds that have already been appropriated that wouldn't cost taxpayers an additional penny," he said in a phone interview on Thursday.



Links to important News

Auto / Auto Ancillaries

China auto investment plans stall amid border tensions

Omega Seiki partners TRANS ACNR for refrigerated containerised electric vehicles

New businesses grow but fail to pull Greaves Cotton out of the red in the September quarter

Banking & Finance

Proposed LVB-DBS merger a remarkable job: RBI board member

Mastercard, USAID join hands for Project Kirana to empower women through financial inclusion

RBI's swift resolution of Lakshmi Vilas Bank to maintain sector stability: S&P

Airtel Payments Bank to expand footprint in West Bengal

Supreme Court to resume hearing on loan moratorium, interest on interest waiver case today

Oil & Gas

India reassessing future oil demand projections and refinery capacity due to pandemic

India to see Rs 10,000 crore investment in LNG stations: Dharmendra Pradhan

India aims to reduce diesel use with Rs 10,000 crore LNG retail push

Metals/Mining/Power

Hybrid tech, new wave of reforms will help India transition to renewable energy, say experts

PM Narendra Modi to inaugurate 3rd global renewable energy meeting & expo on November 26

Renewables' share in energy mix falls marginally to 10.7 pc in Q2: Report

Adani Green Energy doesn't have a guaranteed buyer for \$6 billion solar project in India

Indian steel mills hike prices by Rs 750- Rs 1000 per tonne as demand improves

Govt will look into suggestions of banning iron-ore exports amid supply crisis: Dharmendra Pradhan

IT/Telecom/Media

Voda Idea gets Rs 3,760 crore by selling 11.15% stake in Indus Towers after merger with Infratel

Indian data centres got \$396 million investments in 2020, \$9.5 billion waiting to be put in: Study

Oaktree, Varde offer \$2 billion funding to Vodafone Idea



Links to important News

FMCG/Retail/Textile/Food

Mamaearth appoints Jayant Chauhan as Chief Technology and Product Officer

Titan sees good traction across all businesses during festive season: Company

Handset output catching up with FY20 levels: Companies

FabIndia sales grew 2% during FY20, crossed Rs 1500 crore sale mark

RRVL completes recent round of investments from a bevy of global private equity funds

Singapore arbitration award against deal with Reliance not binding, Future Retail tells court

Pharma/Fertilizers/Healthcare/Chemical

Dr Reddy's starts detailed investigation into anonymous complaint

AstraZeneca COVID-19 shot candidate shows promise among elderly in trials

Infrastructure/Cement/Real Estate

<u>Tighter environment standards to impact coal consumption across Asia: Moody's</u>

<u>L&T bags over Rs 7,000-cr order to construct part of Bullet Train Project</u>





Analyst Certification:

We /I, Deepankar Saha & Jaydeb Dey Research Analyst(s) of SMIFS Limited (in short "SMIFS / the Company"), authors and the names subscribed to this Research Report, hereby certify that all of the views expressed in this Research Report accurately reflect our views about the subject issuer(s) or securities and distributed as per SEBI (Research Analysts) Regulations 2014. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this Research Report. It is also confirmed that We/I, the above mentioned Research Analyst(s) of this Research Report have not received any compensation from the subject companies mentioned in the Research Report in the preceding twelve months and do not serve as an officer, director or employee of the subject companies mentioned in the Research Report.

Terms & Conditions and Other Disclosures:

SMIFS Limited is engaged in the business of Stock Broking, Depository Services, Portfolio Management and Distribution of Financial Products. SMIFS Limited is registered as Research Analyst Entity with Securities & Exchange Board of India (SEBI) with Registration Number – INH300001474.

SMIFS and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Research Analysts. SMIFS generally prohibits its analysts, persons reporting to analysts and their relatives from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

The information and opinions in this Research Report have been prepared by SMIFS and are subject to change without any notice. The Research Report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of SMIFS Limited. While we would endeavor to update the information herein on a reasonable basis, SMIFS is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent SMIFS from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or policies of SMIFS, in circumstances where SMIFS might be acting in an advisory capacity to this company, or in certain other circumstances.

This Research Report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This Research Report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Securities as defined in clause (h) of section 2 of the Securities Contract Act, 1956, includes Financial Instruments, Currency and Commodity Derivatives. Though disseminated to all the customers simultaneously, not all customers may receive this Research Report at the same time. SMIFS will not treat recipients as customers by virtue of their receiving this Research Report. Nothing in this Research Report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this Research Report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. SMIFS accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this Research Report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice. The information given in this report is as of date of this report and there can be no assurance that future results or events will be consistent with this information. The information provided in this report remains, unless otherwise stated, the copyright of SMIFS. All layout, design, original artwork, concepts and intellectual Properties remains the property and copyright of SMIFS and may not be used in any form or for any purpose whatsoever by any party without the express written permission of the SMIFS.





SMIFS shall not be liable for any delay or any other interruption which may occur in presenting the data due to any reason including network (Internet) reasons or snags in the system, breakdown of the system or any other equipment, server breakdown, maintenance shutdown, breakdown of communication services or inability of SMIFS to present the data. In no event shall SMIFS be liable for any damages, including without limitation direct or indirect, special, incidental, or consequential damages, losses or expenses arising in connection with the data presented by the SMIFS through this report.

Participants in foreign exchange transactions may incur risks arising from several factors, including the following: (a) Exchange Rates can be volatile and are subject to large fluctuations; (b) the value of currencies may be affected by numerous market factors, including world and notional economic, political and regulatory events, events in Equity & Debt Markets and changes in interest rates; and (c) Currencies may be subject to devaluation or government imposed Exchange Controls which could affect the value of the Currency. Investors in securities such as Currency Derivatives, whose values are affected by the currency of an underlying security, effectively assume currency risk.

Since associates of SMIFS are engaged in various financial service businesses, they might have financial interests or beneficial ownership in various companies including the subject company/companies mentioned in this Research Report.

SMIFS and its Associates, Officers, Directors, Employees, Research Analysts including their relatives worldwide may: (i) from time to may have long or short positions in, and buy or sell the Securities, mentioned herein or (ii) be engaged in any other transaction involving such Securities and earn brokerage or other compensation or act as a market maker in the Financial Instruments of the Subject Company/ companies mentioned herein or act as an Advisor or Lender/Borrower to such Companies or have other potential/material Conflict of Interest with respect to any recommendation and related information and opinions at the time of the publication of the Research Report. Or at the time of Public Appearance. SMIFS does not have proprietary trades but mat at a future date, may opt for the same with prior intimation to Clients/ Investors and extant Authorities where it may have proprietary long/short position in the above Scrip(s) and therefore should be considered as interested. The views provided herein are general in nature and do not consider Risk Appetite or Investment Objective of any particular Investor; Clients/ Readers/ Subscribers of this Research Report are requested to take independent professional advice before investing. The information provided herein should not be construed as invitation or solicitation to do business with SMIFS.

SMIFS or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the Research Report as of the last day of the month preceding the publication of the Research Report.

SMIFS encourages independence in Research Report preparation and strives to minimize conflict in preparation of Research Report. Accordingly, neither SMIFS and their Associates nor the Research Analysts and their relatives have any material conflict of interest at the time of publication of this Research Report or at the time of the Public Appearance, if any.

SMIFS or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

SMIFS or its associates might have received any compensation from the companies mentioned in the Research Report during the period preceding twelve months from the date of this Research Report for services in respect of managing or co-managing public offerings, corporate finance, investment banking, brokerage services or other advisory service in a merger or specific transaction from the subject company.

SMIFS or its associates might have received any compensation for products or services other than investment banking or brokerage services from the subject companies mentioned in the Research Report in the past twelve months.

SMIFS or its associates or its Research Analysts did not receive any compensation or other benefits whatsoever from the subject companies mentioned in the Research Report or third party in connection with preparation of the Research Report.

Compensation of Research Analysts is not based on any specific Investment Banking or Brokerage Service Transactions.





The Research Analysts might have served as an officer, director or employee of the subject company.

Neither the Research Analysts nor SMIFS have been engaged in market making activity for the companies mentioned in the Research Report.

SMIFS may have issued other Research Reports that are inconsistent with and reach different conclusion from the information presented in this Research Report.

A graph of daily closing prices of the securities/commodities is also available at www.nseindia.com and/or www.bseindia.com, www.nseindia.com and/or www.nseindia.com, and/or <a href="https://www.nseind

SMIFS submit's that no material disciplinary action has been taken on the Company by any Regulatory Authority impacting Equity Research Analysis activities in last 3 years.

This Research Report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject SMIFS and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.

For queries related to compliance of the report, please contact: -

Sudipto Datta, Compliance Officer

SMIFS Limited.

Vaibhav, 4 Lee Road, Kolkata 700020, West Bengal, India.

Contact No.: +91 33 4011 5414 /91 33 6634 5414

Email Id.: compliance@smifs.com | Website: www.smifs.com